2019 Packaging Pharmaceutical Companies 
European Pharmaceutical Review
AUGUST 23, 2022
On- or in-dose authentication means that a security measure or anticounterfeit feature is integrated with the dosage form itself, offering product verification and traceability embedded into each medicine, rather than on the secondary package” WHO estimates that >50 percent of the drugs for sale on the internet are fake. References.
Pharmaceutical Technology
JUNE 19, 2023
Pharmaceutical companies are putting their trust in the immense potential this new generation of medicine has for treating individuals with rare genetic diseases, which currently affect an estimated 280 million patients worldwide. Products are stored and packaged in a dedicated suite by a dedicated team,” explains MacNeir.
This site is protected by reCAPTCHA and the Google Privacy Policy and Terms of Service apply.
European Pharmaceutical Review
APRIL 21, 2023
The ERA therefore needs teeth – which does not mean it should be a barrier to the authorisation of new medicines – but it should require pharmaceutical companies to minimise harmful effects on the environment, which indirectly also harm our health. cited 23Apr]. Available from: [link]. Steenmeijer M, et al. Lancet Planetary Health.
pharmaphorum
APRIL 11, 2022
From patients, patient bodies, pharmaceutical companies, and academia, to regulatory bodies, public institutions, and small and medium-sized enterprises (SMEs), all key stakeholders must come together to help the patients who most need new medicines to access them as quickly as possible. About the author.
pharmaphorum
JUNE 1, 2021
Pharmaceutical companies are accountable for ensuring that their medicine is safe when it comes into the hands of patients. Many countries have introduced serialisation legislation which requires product identifiers to be affixed to each package to provide traceability throughout the distribution supply chain.
Druggist
JULY 20, 2020
Evorel patches have been subject to shortages since 2019. Theramex bought Evorel range of products from Janssen Pharmaceutical Companies (Johnson & Johnson) in October 2019. Theramex committed to increase manufacturing of Evorel products by investing in an additional manufacturer and additional packaging equipment.
Roots Analysis
OCTOBER 30, 2023
Notably, since 2019, more than USD 380 million has been raised / invested by companies engaged in the development of circular RNA, reflecting significant funding activity for circular RNA-based therapies in this domain. Many stakeholders are undertaking initiatives to forge alliances with other industry / non-industry players.
Expert insights. Personalized for you.
98 
Let's personalize your content